Fimbrion Therapeutics
St. Louis, United States· Est. 2016
Fimbrion Awarded Phase I SBIR to Develop Novel Therapeutics to Combat Tuberculosis
Private Company
Total funding raised: $15.8M
About
Fimbrion Awarded Phase I SBIR to Develop Novel Therapeutics to Combat Tuberculosis
Small Molecules
Funding History
2Total raised:$15.8M
Series A$12MNov 15, 2022
Seed$3.8MSep 15, 2020